Outlook Therapeutics, Inc. - Se (OTLKW) |
| 0.03 -0.001 (-1.96%) 04-24 15:47 |
| Open: | 0.155 |
| High: | 0.035 |
| Low: | 0.01 |
| Volume: | 162,240 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 0.74 |
| Resistance 1: | 0.66 |
| Pivot price: | 0.60 |
| Support 1: | 0.53 |
| Support 2: | 0.44 |
| 52w High: | 0.035 |
| 52w Low: | 0.01 |
Financials
| EPS | -55530000.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | -148.358 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -124.00 |
| Return on Assets (ttm) | 255.3 |
| Return on Equity (ttm) | -143.2 |
Company news
Tue, 06 Oct 2026
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion - Yahoo Finance
Fri, 11 Sep 2026
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand - Yahoo Finance
Thu, 10 Sep 2026
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment - Yahoo Finance
Fri, 14 Aug 2026
Outlook Therapeutics, Inc. Q3 2026 Earnings Call Summary - Yahoo Finance
Wed, 12 Aug 2026
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants - Yahoo Finance
Mon, 01 Jun 2026
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) - Yahoo Finance
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
